D
David R. Bell
Researcher at European Chemicals Agency
Publications - 74
Citations - 2286
David R. Bell is an academic researcher from European Chemicals Agency. The author has contributed to research in topics: Aryl hydrocarbon receptor & Receptor. The author has an hindex of 27, co-authored 73 publications receiving 2119 citations. Previous affiliations of David R. Bell include University of Nottingham.
Papers
More filters
Journal ArticleDOI
Endurance Training in Humans Leads to Fiber Type-Specific Increases in Levels of Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 and Peroxisome Proliferator-Activated Receptor-α in Skeletal Muscle
Aaron P. Russell,Jonas Feilchenfeldt,Sylvia N. Schreiber,Manu Praz,Antoinette Crettenand,Charles Gobelet,Christoph A. Meier,David R. Bell,Anastasia Kralli,Anastasia Kralli,Jean Paul Giacobino,Olivier Dériaz +11 more
TL;DR: The increases in PGC-1 and PPAR-alpha levels reported in this study may play an important role in the changes in muscle mitochondria content, oxidative phenotype, and sensitivity to insulin known to be induced by endurance training.
Journal ArticleDOI
Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator
Clifford R. Elcombe,Richard C. Peffer,Douglas C. Wolf,Jason Bailey,Remi Bars,David R. Bell,Russell C. Cattley,Stephen S. Ferguson,David R. Geter,Amber K. Goetz,Jay I. Goodman,Susan D. Hester,Abigail Jacobs,Curtis J. Omiecinski,Rita Schoeny,Wen Xie,Brian G. Lake +16 more
TL;DR: The MOA for PB-induced rodent liver tumor formation was considered to be qualitatively not plausible for humans, supported by data from a number of epidemiological studies conducted in human populations chronically exposed to PB in which there is no clear evidence for increased liver tumor risk.
Journal ArticleDOI
Risk assessment in the 21st century: Roadmap and matrix
Michelle R. Embry,Ammie N. Bachman,David R. Bell,Alan R. Boobis,Samuel M. Cohen,Michael Dellarco,Ian C. Dewhurst,Nancy G. Doerrer,Ronald N. Hines,Angelo Moretto,Timothy P. Pastoor,Richard D. Phillips,J. Craig Rowlands,Jennifer Y. Tanir,Douglas C. Wolf,John E. Doe +15 more
TL;DR: The RISK21 integrated evaluation strategy is a problem formulation-based exposure-driven risk assessment roadmap that takes advantage of existing information to graphically represent the intersection of exposure and toxicity data on a highly visual matrix.
Journal ArticleDOI
A 21st century roadmap for human health risk assessment.
Timothy P. Pastoor,Ammie N. Bachman,David R. Bell,Samuel M. Cohen,Michael Dellarco,Ian C. Dewhurst,John E. Doe,Nancy G. Doerrer,Michelle R. Embry,Ronald N. Hines,Angelo Moretto,Richard D. Phillips,J. Craig Rowlands,Jennifer Y. Tanir,Douglas C. Wolf,Alan R. Boobis +15 more
TL;DR: This paper provides a brief overview of the tiered RISK21 framework called the roadmap and risk visualization matrix, and articulates the core principles derived by RISk21 participants that guided its development.
Journal ArticleDOI
Chromosomal Localisation, Inducibility, Tissue‐Specific Expression and Strain Differences in Three Murine Peroxisome‐Proliferator‐Activated‐Receptor Genes
Paul S. Jones,Richard Savory,Paula Barratt,Alex R. Bell,T. J. Gray,Nancy A. Jenkins,Debra J. Gilbert,Neal G. Copeland,David R. Bell +8 more
TL;DR: Investigation of the tissue-specific distribution revealed that the PPAR alpha RNA was expressed at highest levels in liver, to moderate levels in kidney and brown adipose tissue, and at low levels elsewhere, and the tissue distribution of these receptors suggests an important role in lipid metabolism and toxicity for individual members of thePPAR family.